Consensus ProKidney Corp.

Equities

PROK

KYG7S53R1049

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-07 EDT			5-day change	1st Jan Change
2.42 ^USD	+1.26%		+12.04%	+35.96%

03-25	ProKidney Corp. Announces Key Leadership Appointments Strengthening Clinical and Technical Operations	CI
03-22	ProKidney Posts Wider 2023 Loss	MT

Evolution of the average Target Price on ProKidney Corp.

Price target over the last 5 years

History of analyst recommendation changes

4355cff40424a5f.ztj4wKFTVKHAd7xw0EKHlVE2q6-rZFT0Y3-8GeMM4T4.r6DVqtkQOfaiR_ZBhxrGoxtD2fX4VRuDDRPda9M8jGqcsc2GlyA22bEE3w~36a1d7b9a2cdf70e381c5a228ef12f8d

Analyst Recommendations on ProKidney Corp.

BofA Securities Downgrades ProKidney to Neutral From Buy, Cuts Price Target to $2 From $8	01-02	MT
BTIG Initiates ProKidney With Buy Rating, $16 Price Target	23-07-25	MT
Jefferies Initiates ProKidney With Buy Rating, Price Target is $15	22-12-21	MT
Morgan Stanley Starts ProKidney at Equalweight With $13 Price Target	22-11-10	MT
UBS Initiates Coverage on ProKidney With Buy Rating, $18 Price Target	22-10-18	MT
Citigroup Starts ProKidney at Buy With $16 Price Target	22-10-14	MT
BofA Securities Starts ProKidney at Buy With $14 Price Target	22-09-23	MT
Evercore ISI Initiates Coverage on ProKidney With Outperform Rating	22-09-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.42 USD

Average target price

4.2 USD

Spread / Average Target

+73.55%

High Price Target

6 USD

Spread / Highest target

+147.93%

Low Price Target

2 USD

Spread / Lowest Target

-17.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ProKidney Corp.

BofA Securities
BTIG
Jefferies & Co.
Morgan Stanley
UBS
Citigroup
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar